HIMS Stock Earnings Beat and Bullish Forecast Signal Strength

Hims & Hers Health (NYSE: HIMS) delivered a standout Q1 2025

Hims & Hers HIMS Earnings Recap - Revenue Jumps

Hims & Hers Health (NYSE: HIMS) delivered a standout Q1 2025, with revenue surging 111% year-over-year to $586 million, surpassing expectations. Net income reached $49.5 million, and Adjusted EBITDA nearly tripled to $91.1 million. The subscriber base expanded to 2.4 million, up 38% YoY, with average monthly revenue per subscriber increasing 53% to $84. Hims Inc.

Despite the strong quarter, the company issued a Q2 revenue forecast of $530–$550 million, below analyst expectations of $565 million, leading to a 7% drop in share price. Hims & Hers maintains its full-year 2025 revenue guidance of $2.3–$2.4 billion and raised its Adjusted EBITDA outlook to $295–$335 million.

Looking ahead, the company introduced ambitious 2030 targets: $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA, signaling confidence in its long-term growth strategy.

Key Highlights:

Revenue Surge:

• Q1 revenue came in at $586 million, up 111% year-over-year, beating expectations.

Profitability:

• Reported net income of $49.5 million, compared to a loss of $10.1 million in Q1 2024.
• Adjusted EBITDA grew to $91.1 million, nearly 3x from last year.

Subscriber Growth:

• Active subscriptions grew to 2.4 million, a 38% YoY increase.
• Average revenue per subscriber rose to $84, up 53% YoY.

Q2 Guidance Disappoints:

• Revenue forecast for Q2 is $530–$550 million, which came in below analyst expectations of $565 million — leading to a 7% stock drop.

Full-Year Outlook Maintained:

• FY25 revenue guidance held at $2.3–$2.4 billion.
• Adjusted EBITDA outlook raised to $295–$335 million (from $260–$300M).

2030 Long-Term Targets Announced:

• Management introduced 2030 goals of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA, reflecting strong long-term growth ambitions.

Market Response:

Shares surged as much as 10% post-earnings before pulling back slightly in the red and opening up -7%. Shortly after the open the stock soared with heavy volume and is now +10% for the day showing that while the growth is priced in, the upside story remains intact for long-term believers.

GAR Capital's Updated Rating & Price Target:

“Price target on HIMS is $60 per share.”

This is based on accelerating subscriber growth, raised forward guidance, improving margins, and technical breakout potential above $45.

At current levels, we believe it’s still a solid entry. Technical Targets:

🎯 Target 1: $50 (+15% from here)

🎯 Target 2: $60 (+50%)

🎯 Target 3: $70 — a full +70% move to retest all-time highs.

Read our April 30th article on HIMS Top Pick HIMS Gains 40% - More Upside Ahead?

We also entered a new position in this stock with our Investment Club on May 1st. We are +40% on the dip buy and over +440% on our calls. Excellent trade for both our options & investing club members!

Final Word:

Hims & Hers continues to impress with high-growth fundamentals, sticky subscription models, and forward-thinking healthcare delivery. With AI-driven care personalization and strong retention trends, this name remains one of the top growth healthtech stocks on our radar.

Stock is still below highs, which gives room for opportunity as the telehealth narrative strengthens in 2025. Happy Hunting!

Want more trade ideas and stock insights? Join our free Discord channel where we share top stock picks and exclusive stock ratings throughout the week. You can sign up for instant access at the bottom of our Pricing Page